Immunotherapy in ovarian cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519 - 29; http://dx.doi.org/10.1056/NEJMra041842; PMID: 15590954
   PubMed Web of Science ®Google Scholar
• Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009; 115:2891 - 902; http://dx.doi.org/10.1002/cncr.24317; PMID: 19472394
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203 - 13; http://dx.doi.org/10.1056/NEJMoa020177; PMID: 12529460
   PubMed Web of Science ®Google Scholar
• Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003; 9:1517 - 27; PMID: 12684428
   PubMed Web of Science ®Google Scholar
• Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009; 22:393 - 402; http://dx.doi.org/10.1038/modpathol.2008.191; PMID: 19060844
   PubMed Web of Science ®Google Scholar
• Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012; 124:192 - 8; http://dx.doi.org/10.1016/j.ygyno.2011.09.039; PMID: 22040834
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Powell DJ Jr., Singh N, Coukos G. Immunotherapy for ovarian cancer: what’s next?. J Clin Oncol 2011; 29:925 - 33; http://dx.doi.org/10.1200/JCO.2009.27.2369; PMID: 21079136
   PubMed Web of Science ®Google Scholar
• Leffers N, Fehrmann RS, Gooden MJ, Schulze UR, Ten Hoor KA, Hollema H, et al. Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer 2010; 103:685 - 92; http://dx.doi.org/10.1038/sj.bjc.6605820; PMID: 20664601
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942 - 9; http://dx.doi.org/10.1038/nm1093; PMID: 15322536
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538 - 43; http://dx.doi.org/10.1073/pnas.0509182102; PMID: 16344461
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61:4766 - 72; PMID: 11406550
   PubMed Web of Science ®Google Scholar
• Chu CS, Kim SH, June CH, Coukos G. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008; 8:243 - 57; http://dx.doi.org/10.1586/14737140.8.2.243; PMID: 18279065
   PubMed Web of Science ®Google Scholar
• Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828 - 36; http://dx.doi.org/10.1200/JCO.2011.38.0899; PMID: 22042955
   PubMed Web of Science ®Google Scholar
• Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010; 3:7; http://dx.doi.org/10.1186/1756-8722-3-7; PMID: 20146807
   PubMed Web of Science ®Google Scholar
• Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 1993; 177:1127 - 34; http://dx.doi.org/10.1084/jem.177.4.1127; PMID: 8459207
   PubMed Web of Science ®Google Scholar
• Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010; 3:7; http://dx.doi.org/10.1186/1756-8722-3-7; PMID: 20146807
   PubMed Web of Science ®Google Scholar
• Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997; 15:3399 - 407; PMID: 9363872
   PubMed Web of Science ®Google Scholar
• Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010; 59:293 - 301; http://dx.doi.org/10.1007/s00262-009-0750-3; PMID: 19690855
   PubMed Web of Science ®Google Scholar
• Thibodeaux SR, Curiel TJ. Immune therapy for ovarian cancer: promise and pitfalls. Int Rev Immunol 2011; 30:102 - 19; http://dx.doi.org/10.3109/08830185.2011.567361; PMID: 21557637
   PubMed Web of Science ®Google Scholar
• Nardi M, Cognetti F, Pollera CF, Giulia MD, Lombardi A, Atlante G, et al. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study. J Clin Oncol 1990; 8:1036 - 41; PMID: 2189953
   PubMed Web of Science ®Google Scholar
• Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C, Ragni N, et al. Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study. Anticancer Res 1991; 11:1641 - 3; PMID: 1746921
   PubMed Web of Science ®Google Scholar
• Kaur T, Slavcev RA, Wettig SD. Addressing the challenge: current and future directions in ovarian cancer therapy. Curr Gene Ther 2009; 9:434 - 58; http://dx.doi.org/10.2174/156652309790031148; PMID: 20021329
   PubMed Web of Science ®Google Scholar
• Qian HN, Liu GZ, Cao SJ, Feng J, Ye X. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes. Int J Gynecol Cancer 2002; 12:80 - 5; http://dx.doi.org/10.1046/j.1525-1438.2002.01060.x; PMID: 11860540
   PubMed Web of Science ®Google Scholar
• Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, et al. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol 2010; 116:168 - 72; http://dx.doi.org/10.1016/j.ygyno.2009.10.075; PMID: 19922985
   PubMed Web of Science ®Google Scholar
• Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, et al. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol 2009; 113:210 - 5; http://dx.doi.org/10.1016/j.ygyno.2009.02.007; PMID: 19264351
   PubMed Web of Science ®Google Scholar
• Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 2004; 24:571 - 8; http://dx.doi.org/10.1023/B:JOCI.0000040928.67495.52; PMID: 15359116
   PubMed Web of Science ®Google Scholar
• Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20:2624 - 32; http://dx.doi.org/10.1200/JCO.2002.06.171; PMID: 12039923
   PubMed Web of Science ®Google Scholar
• Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007; 104:12837 - 42; http://dx.doi.org/10.1073/pnas.0703342104; PMID: 17652518
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008; 14:2740 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-07-4619; PMID: 18451240
   PubMed Web of Science ®Google Scholar
• Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012; 61:373 - 84; http://dx.doi.org/10.1007/s00262-011-1100-9; PMID: 21927947
   PubMed Web of Science ®Google Scholar
• Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 2009; 125:2104 - 13; http://dx.doi.org/10.1002/ijc.24597; PMID: 19621448
   PubMed Web of Science ®Google Scholar
• Leffers N, Vermeij R, Hoogeboom BN, Schulze UR, Wolf R, Hamming IE, et al. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int J Cancer 2012; 130:105 - 12; http://dx.doi.org/10.1002/ijc.25980; PMID: 21328579
   PubMed Web of Science ®Google Scholar
• Dohi S, Ohno S, Ohno Y, Takakura M, Kyo S, Soma G, et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Res 2011; 31:2441 - 5; PMID: 21873157
   PubMed Web of Science ®Google Scholar
• Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, et al. Wilms’ tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res 2009; 29:4779 - 84; PMID: 20032435
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 1999; 22:54 - 66; http://dx.doi.org/10.1097/00002371-199901000-00008; PMID: 9924700
   PubMed Web of Science ®Google Scholar
• MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996; 19:59 - 68; http://dx.doi.org/10.1097/00002371-199601000-00007; PMID: 8859725
   PubMed Web of Science ®Google Scholar
• Leffers N, Daemen T, Boezen HM, Melief KJ, Nijman HW. Vaccine-based clinical trials in ovarian cancer. Expert Rev Vaccines 2011; 10:775 - 84; http://dx.doi.org/10.1586/erv.11.42; PMID: 21692699
   PubMed Web of Science ®Google Scholar
• Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63:6076 - 83; PMID: 14522938
   PubMed Web of Science ®Google Scholar
• Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study. Int J Cancer 2011; In press PMID: 22139992
   PubMed Web of Science ®Google Scholar
• Wang B, Kaumaya PT, Cohn DE. Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol Oncol 2010; 119:564 - 70; http://dx.doi.org/10.1016/j.ygyno.2010.07.037; PMID: 20822802
   PubMed Web of Science ®Google Scholar
• Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, et al. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res 2011; 17:3408 - 19; http://dx.doi.org/10.1158/1078-0432.CCR-10-2614; PMID: 21300761
   PubMed Web of Science ®Google Scholar
• Chianese-Bullock KA, Irvin WP Jr., Petroni GR, Murphy C, Smolkin M, Olson WC, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008; 31:420 - 30; http://dx.doi.org/10.1097/CJI.0b013e31816dad10; PMID: 18391753
   PubMed Web of Science ®Google Scholar
• Sabbatini PJ, Kudryashov V, Ragupathi G, Danishefsky SJ, Livingston PO, Bornmann W, et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer 2000; 87:79 - 85; http://dx.doi.org/10.1002/1097-0215(20000701)87:1<79::AID-IJC12>3.0.CO;2-L; PMID: 10861456
   PubMed Web of Science ®Google Scholar
• Odunsi KRK. Lele S et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY-ESO-1 efficiently induces antibody, CD4+ and CD8+ anti tumor immune responses in patients with ovarian cancer. 38th Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. San Diego, CA, USA, 2007.
   Google Scholar
• Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008; 14:3060 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-08-0126; PMID: 18483372
   PubMed Web of Science ®Google Scholar
• Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011; 30:150 - 82; http://dx.doi.org/10.3109/08830185.2011.572210; PMID: 21557641
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14:28 - 36; http://dx.doi.org/10.1038/nm1699; PMID: 18157142
   PubMed Web of Science ®Google Scholar
• Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 2005; 15:1023 - 34; http://dx.doi.org/10.1111/j.1525-1438.2005.00483.x; PMID: 16343178
   PubMed Web of Science ®Google Scholar
• Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, et al. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 2004; 94:340 - 51; http://dx.doi.org/10.1016/j.ygyno.2004.04.024; PMID: 15297171
   PubMed Web of Science ®Google Scholar
• Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009; 32:54 - 65; http://dx.doi.org/10.1097/CJI.0b013e31818b3dad; PMID: 19307994
   PubMed Web of Science ®Google Scholar
• Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009; 27:418 - 25; http://dx.doi.org/10.1200/JCO.2008.17.8400; PMID: 19075271
   PubMed Web of Science ®Google Scholar
• Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2006; 17:1568 - 77; http://dx.doi.org/10.1093/annonc/mdl357; PMID: 17005631
   PubMed Web of Science ®Google Scholar
• Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004; 10:1580 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-03-0056; PMID: 15014007
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006; 12:5503 - 10; http://dx.doi.org/10.1158/1078-0432.CCR-05-2670; PMID: 17000686
   PubMed Web of Science ®Google Scholar
• Nicholson S, Bomphray CC, Thomas H, McIndoe A, Barton D, Gore M, et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother 2004; 53:809 - 16; http://dx.doi.org/10.1007/s00262-004-0522-z; PMID: 15127236
   PubMed Web of Science ®Google Scholar
• Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68:403 - 6; http://dx.doi.org/10.1038/bjc.1993.349; PMID: 8347497
   PubMed Web of Science ®Google Scholar
• Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, Soper JT, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 2007; 120:2710 - 4; http://dx.doi.org/10.1002/ijc.22663; PMID: 17354223
   PubMed Web of Science ®Google Scholar
• Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer 2009; 19:860 - 6; http://dx.doi.org/10.1111/IGC.0b013e3181a8331f; PMID: 19574774
   PubMed Web of Science ®Google Scholar
• Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127:2209 - 21; http://dx.doi.org/10.1002/ijc.25423; PMID: 20473913
   PubMed Web of Science ®Google Scholar
• Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, et al. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 2011; 123:27 - 32; http://dx.doi.org/10.1016/j.ygyno.2011.06.004; PMID: 21733566
   PubMed Web of Science ®Google Scholar
• Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010; 28:1215 - 23; http://dx.doi.org/10.1200/JCO.2009.22.3354; PMID: 19901115
   PubMed Web of Science ®Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21:283 - 90; http://dx.doi.org/10.1200/JCO.2003.10.104; PMID: 12525520
   PubMed Web of Science ®Google Scholar
• Chung MK, Han SS, Roh JK. Synergistic embryotoxicity of combination pyrimethamine and folic acid in rats. Reprod Toxicol 1993; 7:463 - 8; http://dx.doi.org/10.1016/0890-6238(93)90091-K; PMID: 8274822
   PubMed Web of Science ®Google Scholar
• Molthoff CF, Prinssen HM, Kenemans P, van Hof AC, den Hollander W, Verheijen RH. Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer 1997; 80:Suppl 2712 - 20; http://dx.doi.org/10.1002/(SICI)1097-0142(19971215)80:12+<2712::AID-CNCR50>3.0.CO;2-B; PMID: 9406729
   PubMed Web of Science ®Google Scholar
• Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010; 16:5288 - 95; http://dx.doi.org/10.1158/1078-0432.CCR-10-0700; PMID: 20855460
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al, ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365:2484 - 96; http://dx.doi.org/10.1056/NEJMoa1103799; PMID: 22204725
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al, Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365:2473 - 83; http://dx.doi.org/10.1056/NEJMoa1104390; PMID: 22204724
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:5165 - 71; http://dx.doi.org/10.1200/JCO.2007.11.5345; PMID: 18024863
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180 - 6; http://dx.doi.org/10.1200/JCO.2007.12.0782; PMID: 18024865
   PubMed Web of Science ®Google Scholar
• Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief K, et al. Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev:CD007287
   Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299 - 308; http://dx.doi.org/10.1038/nrc2355; PMID: 18354418
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346 - 57; http://dx.doi.org/10.1200/JCO.2005.00.240; PMID: 15800326
   PubMed Web of Science ®Google Scholar
• Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 1991; 51:1934 - 9; PMID: 2004379
   PubMed Web of Science ®Google Scholar
• Lum LG, LeFever AV, Treisman JS, Garlie NK, Hanson JP Jr.. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial. J Immunother 2001; 24:408 - 19; http://dx.doi.org/10.1097/00002371-200109000-00003
   Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12:6106 - 15; http://dx.doi.org/10.1158/1078-0432.CCR-06-1183; PMID: 17062687
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13:98 - 107; http://dx.doi.org/10.3109/14653249.2010.515582; PMID: 20849361
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419 - 26; http://dx.doi.org/10.1038/nature06175; PMID: 17898760
   PubMed Web of Science ®Google Scholar
• Cannon MJ, O’Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther 2009; 9:677 - 88; http://dx.doi.org/10.1517/14712590902932897; PMID: 19456205
   PubMed Web of Science ®Google Scholar
• Hernando JJ, Park TW, Kübler K, Offergeld R, Schlebusch H, Bauknecht T. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002; 51:45 - 52; http://dx.doi.org/10.1007/s00262-001-0255-1; PMID: 11845259
   PubMed Web of Science ®Google Scholar
• Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2012; 61:629 - 41; http://dx.doi.org/10.1007/s00262-011-1081-8; PMID: 22021066
   PubMed Web of Science ®Google Scholar
• Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96:3102 - 8; PMID: 11049990
   PubMed Web of Science ®Google Scholar
• Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008; 105:3005 - 10; http://dx.doi.org/10.1073/pnas.0712237105; PMID: 18287062
   PubMed Web of Science ®Google Scholar
• Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 1987; 47:3317 - 21; PMID: 2953413
   PubMed Web of Science ®Google Scholar
• North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 155:1063 - 74; http://dx.doi.org/10.1084/jem.155.4.1063; PMID: 6460831
   PubMed Web of Science ®Google Scholar
• Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005; 201:1591 - 602; http://dx.doi.org/10.1084/jem.20042167; PMID: 15883172
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100:4712 - 7; http://dx.doi.org/10.1073/pnas.0830997100; PMID: 12682289
   PubMed Web of Science ®Google Scholar
• Alagkiozidis I, Facciabene A, Carpenito C, Benencia F, Jonak Z, Adams S, et al. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J Transl Med 2009; 7:104; http://dx.doi.org/10.1186/1479-5876-7-104; PMID: 20003308
   PubMed Web of Science ®Google Scholar